Rise in demand for early diagnosis is driving the genomics personalized health market size. Personalized genomics is essential for early screening, diagnosis, and individualized treatment as 80% of rare diseases have genetic origins.
Increase in investment in R&D activities is also boosting the genomics personalized health market trajectory. Vendors in the market are investing in human genetics, functional genomics, and Artificial Intelligence/Machine Learning (AI/ML) to expand their product portfolio.
Encouragement and emphasis on R&D are likely to offer lucrative genomics personalized health market opportunities to vendors. To improve R&D, manufacturers are decreasing trial sizes and increasing the speed to market.
Genomic personalized health is a novel approach to healthcare that involves modifying a patient's medical treatment based on genetic information. It is an advanced system developed with a deeper understanding of the human genome.
Genomic personalized health can help identify a variety of complex conditions and help develop more specialized therapies and treatments based on genetic profiling. It can also eliminate certain traditional drugs that might not work or have side effects in a particular patient group.
Genomic personalized health plays a major role in personalized medicine. An individual's genetic profile can be used to decide prevention, diagnosis, and treatment. It can be employed to decide the appropriate drug or therapy at the right dose or schedule.
| Attribute | Detail |
|---|---|
| Drivers |
|
Globally, there is an increasing focus on early disease diagnosis and preventative healthcare. The detection of genetic risk factors and predispositions to diseases, such as cancer, cardiovascular diseases, and neurological disorders, is made possible by genomic testing.
Early diagnosis and best-practice treatment planning are made possible by personal genomics and disease risk assessment. Knowing one's genetic risks through personalized genomics enables people to take preventive action through lifestyle modifications and routine screenings. Hence, increase in demand for early diagnosis is propelling the genomics personalized health market development.
Genetic testing can predict a person's likelihood of developing diseases like colorectal or breast cancer. To reduce the risk of disease, high-risk persons can reduce their exposure to harmful substances, adopt more appropriate lifestyle choices, and use preventive medication.
To enhance therapeutic applications, substantial funding is being directed to genomic research from the public and private sectors. R&D is particularly strong in fields such as population genomics, pharmacogenomics, precision oncology, and genetic disease diagnostics.
Genomic medicine is being advanced by large-scale sequencing projects such as the Asia 100K and the U.K.'s 100K Genomes Project. To jointly create genetic tests and solutions, biopharma businesses, technology companies, and diagnostic labs are increasingly forming alliances. These activities are augmenting the genomics personalized health market revenue.
To boost R&D, various pharmaceutical companies are contributing to genomic data-sharing programs. In December 2021, Seven Bridges Genomics, a bioinformatics ecosystem provider, announced the formation of a new subsidiary, the Unified Patient Network (UPN), to facilitate clinical research and collaboration between participating health systems and biopharma companies with a focus on advancing precision medicine and improving patient care.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest genomics personalized healthcare market analysis, North America held largest share in 2023. Increase in healthcare expenditure and rise in awareness of and demand for personalized medicine are propelling the market dynamics of the region.
Advancements in genomics technologies, presence of large pharmaceutical companies and research organizations, and rise in prevalence of chronic diseases are also fueling the genomics personalized health market share in North America.
Since personalized medicine is currently preferred for treating various types of illnesses, medication discovery and research on specific illnesses are interrelated. Various companies are developing customized diagnosis products.
In January 2021, Illumina, Inc. created the TruSight Oncology 500 (TSO 500) assay, which can effectively identify up to 523 cancer biomarkers using nucleic acids from the tumor.
Key players operating in the genomics personalized health market landscape are offering robust precision medicine genomics services and programs that leverage predictive analytics to provide targeted treatment regimens. These services help prevent and treat diseases at their earliest stages when they are most treatable.
In April 2021, NorthShore University HealthSystem (NorthShore) and health intelligence company Sema4 announced the rollout of a system-wide data-driven genomics initiative aimed at providing patients and their care team with early detection of disease onset.
QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Hoffmann-La Roche AG, Lonza Group, Invitae Corp, Genetic Technologies Limited, Interleukin Genetics Inc., Eastern Biotech and Life Sciences, DNA Genotek Inc., uBiome, Inc., and XCode Life Sciences Private Limited are some of the key players operating in genomics personalized health industry.
These companies have been profiled in the genomics personalized health market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 9.1 Bn |
| Market Forecast (Value) in 2034 | US$ 33.0 Bn |
| Growth Rate (CAGR) | 12.2% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 9.1 Bn in 2023
It is projected to advance at a CAGR of 12.2% from 2024 to 2034
Rise in demand for early diagnosis and increase in investment in R&D activities
North America was the leading region in 2023
QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Hoffmann-La Roche AG, Lonza Group, Invitae Corp, Genetic Technologies Limited, Interleukin Genetics Inc., Eastern Biotech and Life Sciences, DNA Genotek Inc., uBiome, Inc., and XCode Life Sciences Private Limited
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Genomics Personalized Health Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Genomics Personalized Health Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Genomics Personalized Health Market Analysis and Forecast, By Technology
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, By Technology, 2020-2034
6.3.1. NGS Platform
6.3.2. RT-PCR
6.3.3. Microarray
6.3.4. Genetic Analyzer
6.3.5. Others
6.4. Market Attractiveness Analysis, By Technology
7. Global Genomics Personalized Health Market Analysis and Forecast, by Test Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Test Type, 2020-2034
7.3.1. Oncology Testing
7.3.2. Infectious Disease Testing
7.3.3. Orphan Disease Testing
7.3.4. Autoimmune Disease Testing
7.3.5. Obstetrics Testing
7.3.6. Others
7.4. Market Attractiveness Analysis, by Test Type
8. Global Genomics Personalized Health Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Academics & Research Institutes
8.3.2. Diagnostic Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Genomics Personalized Health Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Genomics Personalized Health Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, By Technology, 2020-2034
10.3.1. NGS Platform
10.3.2. RT-PCR
10.3.3. Microarray
10.3.4. Genetic Analyzer
10.3.5. Others
10.4. Market Value Forecast, by Test Type, 2020-2034
10.4.1. Oncology Testing
10.4.2. Infectious Disease Testing
10.4.3. Orphan Disease Testing
10.4.4. Autoimmune Disease Testing
10.4.5. Obstetrics Testing
10.4.6. Others
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Academics & Research Institutes
10.5.2. Diagnostic Centers
10.5.3. Others
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Technology
10.7.2. By Test Type
10.7.3. By End-user
10.7.4. By Country
11. Europe Genomics Personalized Health Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, By Technology, 2020-2034
11.3.1. NGS Platform
11.3.2. RT-PCR
11.3.3. Microarray
11.3.4. Genetic Analyzer
11.3.5. Others
11.4. Market Value Forecast, by Test Type, 2020-2034
11.4.1. Oncology Testing
11.4.2. Infectious Disease Testing
11.4.3. Orphan Disease Testing
11.4.4. Autoimmune Disease Testing
11.4.5. Obstetrics Testing
11.4.6. Others
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Academics & Research Institutes
11.5.2. Diagnostic Centers
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Technology
11.7.2. By Test Type
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Genomics Personalized Health Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, By Technology, 2020-2034
12.3.1. NGS Platform
12.3.2. RT-PCR
12.3.3. Microarray
12.3.4. Genetic Analyzer
12.3.5. Others
12.4. Market Value Forecast, by Test Type, 2020-2034
12.4.1. Oncology Testing
12.4.2. Infectious Disease Testing
12.4.3. Orphan Disease Testing
12.4.4. Autoimmune Disease Testing
12.4.5. Obstetrics Testing
12.4.6. Others
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Technology
12.6.2. By Test Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Genomics Personalized Health Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, By Technology, 2020-2034
13.3.1. NGS Platform
13.3.2. RT-PCR
13.3.3. Microarray
13.3.4. Genetic Analyzer
13.3.5. Others
13.4. Market Value Forecast, by Test Type, 2020-2034
13.4.1. Oncology Testing
13.4.2. Infectious Disease Testing
13.4.3. Orphan Disease Testing
13.4.4. Autoimmune Disease Testing
13.4.5. Obstetrics Testing
13.4.6. Others
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Academics & Research Institutes
13.5.2. Diagnostic Centers
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Technology
13.7.2. By Test Type
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Genomics Personalized Health Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, By Technology, 2020-2034
14.3.1. NGS Platform
14.3.2. RT-PCR
14.3.3. Microarray
14.3.4. Genetic Analyzer
14.3.5. Others
14.4. Market Value Forecast, by Test Type, 2020-2034
14.4.1. Oncology Testing
14.4.2. Infectious Disease Testing
14.4.3. Orphan Disease Testing
14.4.4. Autoimmune Disease Testing
14.4.5. Obstetrics Testing
14.4.6. Others
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Academics & Research Institutes
14.5.2. Diagnostic Centers
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Technology
14.7.2. By Test Type
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. QIAGEN
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Illumina, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Thermo Fisher Scientific, Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Bio-Rad Laboratories, Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Hoffmann-La Roche AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Lonza Group
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Invitae Corp
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Genetic Technologies Limited
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Interleukin Genetics Inc.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Eastern Biotech and Life Sciences
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. DNA Genotek Inc.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. uBiome, Inc.
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. XCode Life Sciences Private Limited
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
List of Tables
Table 01: Global Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034
Table 02: Global Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034
Table 03: Global Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 04: Global Genomics Personalized Health Market Size (US$ Mn) Forecast, by Region, 2020-2034
Table 05: North America Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country, 2020-2034
Table 06: North America Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034
Table 07: North America Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034
Table 08: North America Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 09: Europe Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034
Table 11: Europe Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034
Table 12: Europe Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034
Table 15: Asia Pacific Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034
Table 16: Asia Pacific Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 17: Latin America Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034
Table 19: Latin America Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034
Table 20: Latin America Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast, By Technology, 2020-2034
Table 23: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast, by Test Type, 2020-2034
Table 24: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Genomics Personalized Health Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Genomics Personalized Health Market Revenue (US$ Mn), By Technology, 2023
Figure 03: Global Genomics Personalized Health Market Value Share, By Technology, 2023
Figure 04: Global Genomics Personalized Health Market Revenue (US$ Mn), by Test Type, 2023
Figure 05: Global Genomics Personalized Health Market Value Share, by Test Type, 2023
Figure 06: Global Genomics Personalized Health Market Revenue (US$ Mn), by End-user, 2023
Figure 07: Global Genomics Personalized Health Market Value Share, by End-user, 2023
Figure 08: Global Genomics Personalized Health Market Value Share, by Region, 2023
Figure 09: Global Genomics Personalized Health Market Value (US$ Mn) Forecast, 2020-2034
Figure 10: Global Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034
Figure 11: Global Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 13: Global Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 14: Global Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034
Figure 16: Global Genomics Personalized Health Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Genomics Personalized Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Genomics Personalized Health Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Genomics Personalized Health Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034
Figure 22: North America Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 23: North America Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034
Figure 24: North America Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 26: North America Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034
Figure 27: Europe Genomics Personalized Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Genomics Personalized Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Genomics Personalized Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034
Figure 31: Europe Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 32: Europe Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Europe Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 35: Europe Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034
Figure 36: Asia Pacific Genomics Personalized Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Genomics Personalized Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Genomics Personalized Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034
Figure 40: Asia Pacific Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 41: Asia Pacific Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034
Figure 42: Asia Pacific Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 44: Asia Pacific Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034
Figure 45: Latin America Genomics Personalized Health Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Genomics Personalized Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Genomics Personalized Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034
Figure 49: Latin America Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 50: Latin America Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Latin America Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 53: Latin America Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034
Figure 54: Middle East & Africa Genomics Personalized Health Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Genomics Personalized Health Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Genomics Personalized Health Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Genomics Personalized Health Market Value Share Analysis, By Technology, 2023 and 2034
Figure 58: Middle East & Africa Genomics Personalized Health Market Value Share Analysis, by Test Type, 2023 and 2034
Figure 59: Middle East & Africa Genomics Personalized Health Market Value Share Analysis, by End-user, 2023 and 2034
Figure 60: Middle East & Africa Genomics Personalized Health Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Genomics Personalized Health Market Attractiveness Analysis, by Test Type, 2024-2034
Figure 62: Middle East & Africa Genomics Personalized Health Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Genomics Personalized Health Market
*86 figures and 60 tables includes